Urinary interleukin-8 predicts the response of standard and low dose intravesical bacillus calmette-guerin (modified Danish 1331 strain) for superficial bladder cancer

Journal of Urology

Volumn 168, Issue 5, 2002, Pages 2232-2235

  Kumar, Anant ^a   Dubey, Deepak ^a   Bansal, Pradeep ^a   Mandhani, Anil ^a   Naik, Sita ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Bladder; Bladder neoplasms; Interleukin 8; Mycobacterium bovis

Indexed keywords

BCG VACCINE; ISONIAZID;

ADULT; AGED; ARTHRALGIA; ARTICLE; BCG VACCINATION; BLADDER CARCINOMA; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER RISK; CENTRIFUGATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYSTITIS; CYTOKINE RELEASE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; KNEE; MALE; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN URINE LEVEL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RASH; STORAGE TEMPERATURE; SUPERFICIAL CANCER; TREATMENT OUTCOME; URINALYSIS;

EID: 0036837255     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)64361-3     Document Type: Article

References (16)

1. Rischmann, P., Desgrandchamps, F., Malavaud, B. and Chopin, D. K.: BCG intravesical instillations: recommendations for side-effects management. Eur Urol, suppl., 37: 33, 2000
2. Van der Meijden, A. P., Hall, R. R., Kurth, K. H., Bouffioux, C. H. and Sylvester, R.: Phase II trials in Ta, T1 cancer. The marker tumour concept. Br J Urol, 77: 634, 1996
3. de Reijke, T. M., de Boer, E. C., Kurth, K. H. and Schamhart, D. H. J.: Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol, 155: 477, 1996
4. Thalmann, G. N., Dewald, B., Baggiolini, M. and Studer, U. E.: Interleukin-8 expression in the urine after bacillus Calmette-Guerin therapy: a potential prognostic factor of tumor recurrence and progression. J Urol, 158: 1340, 1997
5. Rabinowitz, R., Smith, D. S., Tiemann, D. D. and Hudson, M. A.: Urinary interleukin-8/creatinine level as a predictor of response to intravesical bacillus Calmette-Guerin therapy in bladder tumor patients. J Urol, 158: 1728, 1997
6. Jackson, A. M., Ivshina, A. V., Senko, O., Kuznetsova, A., Sundan, A., O'Donnell, M. A. et al: Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndromes analysis. J Urol, 159: 1054, 1998
7. Thalmann, G. N., Sermier, A., Rentsch, C., Mohrle, K., Cecchini, M. G. and Studer, U. E.: Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. J Urol, 164: 2129, 2000
8. Bassi, P., Spinadin, R., Carando, R., Balta, G. and Pagano, F.: Modified induction course: a solution to side-effects? Eur Urol, suppl., 37: 31, 2000
9. Lebret, D., Bohin, D., Kassardjian, Z., Herve, J.-M., Molinie, V., Barre, P. et al: Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations. J Urol, 163: 63, 2000
10. Yalcinkaya, F., Kamis, L., Ozteke, O., Gunlusoy, B., Yigitbasi, O. and Unal, S.: Prospective randomized comparison of intravesical BCG therapy with standard dose versus low doses in superficial bladder carcinoma. Int Urol Nephrol, 30: 41, 1998
11. de Boer, E. C., Somogyi, L., de Ruiter, G. J., de Reijke, T. M., Kurth, K. H. and Schamhart, D. H.: Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer. Urol Res, 25: 31, 1997
12. Friedland, J. S.: Chemotactic cytokines and tuberculosis. Biochem Soc Trans, 22: 310, 1994
13. Lüftenegger, W., Ackermann, D. K., Futterlieb, A., Kraft, R., Minder, C. E., Nadelhaft, P. et al: Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors. J Urol, 155: 483, 1996
14. Saint, F., Patard, J. J., Irani, J., Salomon, L., Hoznek, A., Legrand, P. et al: Leukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder cancer. Urology, 57: 617, 2001
15. Gan, Y. H., Mahendran, R., James, K., Lawrencia, C. and Esuvaranathan, K.: Evaluation of lymphocytic responses after treatment with Bacillus Calmette-Guerin and interferon-alpha2b for superficial bladder cancer. Clin Immunol, 90: 230, 1999
16. Mack, D., Holtl, W., Bassi, P., Brausi, M., Ferrari, P., de Balincourt, C. et al: The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder. J Urol, 165: 401, 2001